Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Use and Safety of Peripherally Inserted Venous Catheters Versus Central Venous Catheters for Patients With Lymphoma Receiving Frontline Anthracycline-based Chemotherapy.

Created on 19 Nov 2026

Authors

Yun Kyoung Tiger, Danny Luan, Patrick Glennan, Zaibunnisa Kamran, Kyle Meinert, Adrienne Nevded, Joseph Lukowski, Abdus Samad Minjah, Alexander Sanjurjo, Melinda Harbhajan, Jacqueline Norrell, Salmaan Mubeen, Frederique St-Pierre, Gabriel Kindl, Keem Patel, Olutobi Adewale, Harris Allen, Cecilia Merrigan, Emily Brigham, Sophia Luyten, Srilatha Dasari, Fan Ling, Hao Liu, Zulfa Omer, Matthew Matasar, Joanna Rhodes, Seda Tolu, Grzegorz Nowakowski, Carla Casulo, Matthew Lunning, Peter Martin, Deepa Jagadeesh, Andrew M Evens

Published in

Clinical lymphoma, myeloma & leukemia. Oct 28, 2026. Epub Oct 28, 2026.

Abstract

Peripheral intravenous catheters (PIVs) for the administration of anthracycline-based chemotherapy have the potential risk of vascular and tissue injury due to extravasation of vesicant agents. Central venous catheters (CVCs) are frequently utilized to mitigate this. This multicenter retrospective real-world analysis (RWA) evaluated complications associated with PIVs versus CVCs for the administration of anthracycline-based chemotherapy in patients with lymphoma.
We conducted a RWA across 9 US medical centers, including adults with newly diagnosed lymphoma who received anthracycline-based chemotherapy via PIV or CVC between 2010 and 2025. Detailed baseline characteristics and safety outcomes were collected, applying standard definitions for extravasation and other recognized complications. Incidence rates of safety outcomes were calculated, and multivariable Poisson regression models were applied to adjust for confounders.
In total, 1776 patients were included: 1077 with CVCs, 886 with PIVs, and 187 with both. The most common diagnoses were large B-cell lymphomas, followed by Hodgkin lymphoma, and then T-cell lymphoma. In total, there were 5464 and 4049 treatment cycles in the CVC and PIV cohorts, respectively. There was one definite case of extravasation with PIV use (incidence rate 0.19 events per 1000 infusion-cycles), compared to no cases with CVC use. PIV use was more commonly associated with flare, phlebitis, and pain, whereas CVC use was more commonly associated with deep vein thrombosis; other complications were not different between cohorts. Rates of extravasation and other complications were low in both PIV and CVC cohorts.
Altogether, PIVs represent a viable modality for patients with lymphoma requiring anthracycline-based chemotherapy.

PMID:
43052097
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement